Group 1 - Goldman Sachs has downgraded Roche Holding AG to a sell rating, maintaining a target price of 265 Swiss Francs [1] - The downgrade is related to Roche's Parkinson's disease candidate drug failing to meet key objectives in mid-stage studies, although results suggest potential clinical benefits in early Parkinson's disease treatment [1] - Other investment banks, including JPMorgan and Deutsche Bank, have also issued sell ratings on Roche Holding AG [2] Group 2 - Roche Holding AG is a research-based healthcare company with operations in pharmaceuticals and diagnostics [2] - Despite recent progress in certain areas, such as the approval of Vabysmo pre-filled syringes in Europe and positive long-term data in lymphoma treatment, setbacks in Parkinson's disease drug development and negative ratings from multiple investment banks have put pressure on its stock price [2]
高盛：给予罗氏控股公司卖出评级